Polyethylene glycol
- Generic Name
- Polyethylene glycol
- Brand Names
- Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 25322-68-3
- Unique Ingredient Identifier
- 3WJQ0SDW1A
- Background
Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the...
- Indication
Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.
- Associated Conditions
- Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
- Associated Therapies
- Bowel preparation therapy, Eye lubrication
A Study Comparing PEG-3350 (Miralax) and Gatorade With PEG-ELS (Golytely) for Bowel Preparation Prior to Colonoscopy
- Conditions
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2012-03-14
- Target Recruit Count
- 400
- Registration Number
- NCT01028573
- Locations
- 🇺🇸
VA Long Beach Healthcare System, Long Beach, California, United States
Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 203
- Registration Number
- NCT00770432
Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 138
- Registration Number
- NCT00765557
Probiotics for Eradication of Carbapenem Resistant Klebsiella Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2008-07-25
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 60
- Registration Number
- NCT00722410
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
Small Bowel Cleansing Prior to Video Capsule Endoscopy Examination
- Conditions
- Interventions
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 198
- Registration Number
- NCT00677794
- Locations
- 🇨🇦
Hotel Dieu Hospital, Kingston, Ontario, Canada
Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation
- Conditions
- Interventions
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2008-10-07
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 67
- Registration Number
- NCT00603681
- Locations
- 🇫🇮
Tampereen sotainvalidien Veljeskoti, Tampere, Finland
🇫🇮Vire Koti Kaukaharju assisted-living facility, Tampere, Finland
🇫🇮Taatala assested-living facility, Tampere, Finland
Polyethylene Glycol Versus Sodium Phosphate for Colon Preparation After Failure of First Preparation for Colonoscopy
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00558376
- Locations
- 🇮🇱
Sheba_Medical_Center, Tel-Hashomer, Israel
A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- Braintree Laboratories
- Target Recruit Count
- 25
- Registration Number
- NCT00319670
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.